Lily Mounjaro: clearing up the name behind the medicine

The biggest misconception: "Lily Mounjaro" is not a different product

Type "lily mounjaro" into a search engine and you might wonder whether you're looking at a variant, a generic, or a cheaper alternative. You're not. The phrase is simply a common shorthand, people pairing the manufacturer's name with the brand name. Eli Lilly is the company; Mounjaro is the medicine. There is one licensed product: tirzepatide, sold under the Mounjaro name, supplied in the UK through the licensed supply chain. There are no official "Lily-brand" variants, no alternative formulations, and no legitimate cheaper copies. If a seller is offering something described as a budget version or an equivalent that doesn't require a prescription, that's a serious red flag, the MHRA has warned repeatedly about counterfeit weight-loss pens circulating online and via social media, some of which have caused hospitalisations. The safest starting point is understanding exactly what the real product is, and our Lilly Mounjaro page explains the relationship between the manufacturer and the medicine in plain terms.

Mounjaro is a once-weekly subcutaneous injection delivered via a pre-filled KwikPen. Each pen contains four weekly doses. You can read a detailed overview of tirzepatide on the NHS medicines page for tirzepatide, which covers how it works, common side effects, and storage guidance at a patient level.

How Mounjaro actually works, and why it differs from other weight-loss injections

Tirzepatide is described as a dual agonist because it activates two receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both are gut hormones involved in appetite regulation and blood-sugar control. Activating both pathways together slows how quickly the stomach empties, increases feelings of fullness after eating, and reduces overall appetite. No other weight-loss injection currently licensed in the UK works on both pathways simultaneously, this is the pharmacological distinction that sets Mounjaro apart from semaglutide-based medicines.

The trial programme that underpins the UK licence is called SURMOUNT. SURMOUNT-1 randomised 2,539 adults with obesity who did not have type 2 diabetes, following them for 72 weeks. At the 15 mg dose, average body-weight reduction reached around 20–21%. A later head-to-head trial, SURMOUNT-5, compared tirzepatide directly with semaglutide 2.4 mg over the same period; tirzepatide produced greater average weight loss. These are the figures NICE relied on when issuing its recommendation for tirzepatide in December 2024, published as NICE technology appraisal TA1026. Results in clinical trials and in real-world practice will vary between individuals, the figures are averages, not guarantees.

If you want to dig into the mechanism in more detail, the lilly tirzepatide page covers the science more fully.

Who Mounjaro is licensed for, and what NICE recommends on the NHS

The UK licence covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea. That is the private eligibility threshold; on a private prescription, a prescriber weighs the whole clinical picture, not the BMI figure alone.

NHS access follows stricter criteria set out in NICE TA1026. Currently, patients need a BMI of 40 or above plus four or more qualifying conditions from a defined list. A second NHS cohort opened in June 2026 for those with a BMI of 35–39.9 alongside four or more of the same conditions. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NHS rollout is phased, eligibility is assessed locally, and waiting times vary considerably. Private treatment through a registered pharmacy is the alternative for people who don't meet NHS criteria yet, or who would rather not wait.

Mounjaro is not recommended for use during pregnancy, breastfeeding, or when actively trying to conceive, and it is not licensed for anyone under 18. Certain medical histories (including a personal or family history of medullary thyroid carcinoma) require careful prescriber discussion before treatment begins. If you'd like a fuller picture of what Eli Lilly Mounjaro involves as a treatment, including the prescribing standards and what the manufacturer requires of licensed suppliers, that page sets it out clearly. For a longer look at how the cost side works, the Mounjaro prices page sets out what a private prescription genuinely includes. If you're curious about the broader landscape of weight-loss options, our treatment overview compares the approaches currently available through nume.

Getting a legitimate Mounjaro prescription in the UK

Mounjaro is a prescription-only medicine. The legal route in the UK is a clinical consultation with a qualified prescriber who can assess your health history, current medicines, and suitability. At nume, that consultation is free and reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not an automated system. Identity and weight are verified before treatment is approved, and the GP you're registered with is notified in line with GPhC guidance. Once approved, orders placed before 12 pm on a working day are dispatched the same day via DPD, arriving the next working day in plain, unbranded packaging at no extra charge.

It's worth knowing that if you order on, say, a bank holiday Monday, dispatch moves to Tuesday, something a few patients catch by surprise around Christmas or Easter. The frequently asked questions page covers delivery timings and what happens if you need to pause treatment. If you'd find it helpful to see the pen demonstrated before you begin, our Lilly Mounjaro video walks through the injection process step by step. You can also visit our Mounjaro page for a consolidated overview of the treatment, eligibility, and how to get started through a registered UK pharmacy. You can check that any UK online pharmacy you consider is genuine by searching the GPhC pharmacy register, it takes about thirty seconds and is the single most useful check you can do. Our clinical team's approach and credentials are described on the about us page. When you're ready to take the next step, our prescribers are available seven days a week through the consultation page, speak to our prescribers and find out whether Mounjaro is the right fit for you.